Small-cell lung cancer in 2016: Shining light on novel targets and therapies

Nat Rev Clin Oncol. 2017 Feb;14(2):75-76. doi: 10.1038/nrclinonc.2016.203. Epub 2016 Dec 13.

Authors

Charles M Rudin¹, John T Poirier¹

Affiliation

¹ Molecular Pharmacology Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; and at the Weill Cornell Medical College, New York, New York, USA.

PMID: 27958293
DOI: 10.1038/nrclinonc.2016.203

No abstract available

MeSH terms

Animals
Antineoplastic Agents, Immunological / therapeutic use
Biomarkers, Tumor / analysis
Biomarkers, Tumor / antagonists & inhibitors
Cell Cycle Checkpoints / drug effects
Cell Cycle Checkpoints / physiology
Disease Models, Animal
Humans
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors
Intracellular Signaling Peptides and Proteins / biosynthesis
Lung Neoplasms / genetics
Lung Neoplasms / physiopathology
Lung Neoplasms / therapy*
Membrane Proteins / antagonists & inhibitors
Membrane Proteins / biosynthesis
Mice
Neoplasm Metastasis / genetics
Small Cell Lung Carcinoma / genetics
Small Cell Lung Carcinoma / physiopathology
Small Cell Lung Carcinoma / therapy*
T-Lymphocytes / drug effects
T-Lymphocytes / physiology

Substances

Antineoplastic Agents, Immunological
Biomarkers, Tumor
DLL3 protein, human
Intracellular Signaling Peptides and Proteins
Membrane Proteins